27 results on '"Maas, R.J.H."'
Search Results
2. Circulating permeability factor(s) in primary focal segmental glomerulosclerosis
- Author
-
Nijenhuis, T., Vlag, J. van der, Gool, A.J. van, Maas, R.J.H., Braanker, D.J.W. den, Nijenhuis, T., Vlag, J. van der, Gool, A.J. van, Maas, R.J.H., and Braanker, D.J.W. den
- Abstract
Contains fulltext : 297666.pdf (Publisher’s version ) (Open Access), Radboud University, 29 november 2023, Promotores : Nijenhuis, T., Vlag, J. van der, Gool, A.J. van Co-promotor : Maas, R.J.H., 159 p.
- Published
- 2023
3. Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling
- Author
-
Jansen, J., Berge, B.T. van den, Broek, M.L. van den, Maas, R.J.H., Daviran, D., Willemsen, B.K., Roverts, R.C., Giovanni, G.L.V. Di, Mooren, F., Wetzels, Roy, Parr, N.M.J., Steenbergen, E., Nijenhuis, T., Dijkman, H.B., Kar, N.C.A.J. van de, Wetzels, J.F.M., Akiva, A., Vlag, J. van der, Schreuder, M.F., Smeets, B., Jansen, J., Berge, B.T. van den, Broek, M.L. van den, Maas, R.J.H., Daviran, D., Willemsen, B.K., Roverts, R.C., Giovanni, G.L.V. Di, Mooren, F., Wetzels, Roy, Parr, N.M.J., Steenbergen, E., Nijenhuis, T., Dijkman, H.B., Kar, N.C.A.J. van de, Wetzels, J.F.M., Akiva, A., Vlag, J. van der, Schreuder, M.F., and Smeets, B.
- Abstract
Item does not contain fulltext
- Published
- 2022
4. Minimal Change Disease: More Than a Podocytopathy?
- Author
-
Maas, R.J.H., Nijenhuis, T., Vlag, J. van der, Maas, R.J.H., Nijenhuis, T., and Vlag, J. van der
- Abstract
Item does not contain fulltext
- Published
- 2022
5. Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis
- Author
-
Braanker, D.J.W. den, Maas, R.J.H., Parr, N.M.J., Deegens, J.K., Smeets, B., Wetzels, J.F.M., Vlag, J. van der, Nijenhuis, T., Braanker, D.J.W. den, Maas, R.J.H., Parr, N.M.J., Deegens, J.K., Smeets, B., Wetzels, J.F.M., Vlag, J. van der, and Nijenhuis, T.
- Abstract
Contains fulltext : 283473.pdf (Publisher’s version ) (Open Access), Recurrence of proteinuria after kidney transplantation in primary focal segmental glomerulosclerosis (FSGS) is unpredictable. Several putative circulating permeability factors (CPFs) have been suggested, but none have been validated. A clinically relevant experimental model is required that demonstrates the presence of CPF(s) in patient material, to study CPF(s) and possibly predict recurrence in patients. We aimed to develop a FSGS-prone Thy-1.1 transgenic mouse model with accelerated proteinuria after injection of samples from patients with FSGS. The Thy-1.1 transgene was backcrossed into 5 mouse strains. The age of onset and severity of spontaneous proteinuria varied between the different genetic backgrounds. 129X1/SvThy-1.1 and 129S2/SvPasThy-1.1 mice displayed proteinuria at 4 weeks, whereas Balb/cThy-1.1 and C57BL/6JThy-1.1 mice developed proteinuria from 6 weeks, and were used further. We determined the maximum protein dose that could be injected without causing protein overload in each background. Balb/cThy-1.1 and C57BL/6JThy-1.1 males and females were injected with presumably CPF-containing plasmapheresis effluent from 6 FSGS patients, which induced albuminuria particularly in Balb/cThy-1.1 males. Unfortunately, no response could be detected when using sera instead of plasmapheresis effluent, serum being more clinically relevant in the context of predicting FSGS recurrence. Considering the differences between responses elicited by serum and plasmapheresis effluent, simultaneously collected serum, plasma, and plasmapheresis effluent were tested. Whereas we could detect responses using a validated in vitro model, none of these presumably CPF-containing samples induced proteinuria in Balb/cThy-1.1 males. Thus, we have extensively tested the Thy-1.1 mouse model on different genetic backgrounds with proteinuria after injection of FSGS patient material as clinically relevant readout. The Balb/cThy-1.1 male mouse strain demonstrated the most promising results, bu
- Published
- 2022
6. Association of obesity with 3-month mortality in kidney failure patients with COVID-19
- Author
-
Tantisattamo, E., Imhof, C., Jager, K.J., Hilbrands, L.B., Guidotti, R., Islam, M., Katicic, D., Konings, C., Molenaar, F.M., Nistor, I., Noordzij, M., Ferrero, M.L. Rodríguez, Verhoeven, M.A., Vries, A.P.J de, Kalantar-Zadeh, K., Logt, A. van de, Maas, R.J.H., Duivenvoorden, R., Gansevoort, R.T., Vart, P., Tantisattamo, E., Imhof, C., Jager, K.J., Hilbrands, L.B., Guidotti, R., Islam, M., Katicic, D., Konings, C., Molenaar, F.M., Nistor, I., Noordzij, M., Ferrero, M.L. Rodríguez, Verhoeven, M.A., Vries, A.P.J de, Kalantar-Zadeh, K., Logt, A. van de, Maas, R.J.H., Duivenvoorden, R., Gansevoort, R.T., and Vart, P.
- Abstract
Contains fulltext : 251898.pdf (Publisher’s version ) (Open Access), BACKGROUND: In the general population with coronavirus disease 2019 (COVID-19), obesity is associated with an increased risk of mortality. Given the typically observed obesity paradox among patients on kidney function replacement therapy (KFRT), especially dialysis patients, we examined the association of obesity with mortality among dialysis patients or living with a kidney transplant with COVID-19. METHODS: Data from the European Renal Association COVID-19 Database (ERACODA) were used. KFRT patients diagnosed with COVID-19 between 1 February 2020 and 31 January 2021 were included. The association of Quetelet's body mass index (BMI) (kg/m(2)), divided into: <18.5 (lean), 18.5-24.9 (normal weight), 25-29.9 (overweight), 30-34.9 (obese I) and ≥35 (obese II/III), with 3-month mortality was investigated using Cox proportional-hazards regression analyses. RESULTS: In 3160 patients on KFRT (mean age: 65 years, male: 61%), 99 patients were lean, 1151 normal weight (reference), 1160 overweight, 525 obese I and 225 obese II/III. During follow-up of 3 months, 28, 20, 21, 23 and 27% of patients died in these categories, respectively. In the fully adjusted model, the hazard ratios (HRs) for 3-month mortality were 1.65 [95% confidence interval (CI): 1.10, 2.47], 1 (ref.), 1.07 (95% CI: 0.89, 1.28), 1.17 (95% CI: 0.93, 1.46) and 1.71 (95% CI: 1.27, 2.30), respectively. Results were similar among dialysis patients (N = 2343) and among those living with a kidney transplant (N = 817) (P(interaction) = 0.99), but differed by sex (P(interaction) = 0.019). In males, the HRs for the association of aforementioned BMI categories with 3-month mortality were 2.07 (95% CI: 1.22, 3.52), 1 (ref.), 0.97 (95% CI: 0.78. 1.21), 0.99 (95% CI: 0.74, 1.33) and 1.22 (95% CI: 0.78, 1.91), respectively, and in females corresponding HRs were 1.34 (95% CI: 0.70, 2.57), 1 (ref.), 1.31 (95% CI: 0.94, 1.85), 1.54 (95% CI: 1.05, 2.26) and 2.49 (95% CI: 1.62, 3.84), respectively. CONCLUSION: In KFRT patients
- Published
- 2022
7. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study
- Author
-
Goffin, E., Candellier, A., Vart, P., Noordzij, M., Arnol, M., Covic, A., Lentini, P., Malik, S., Reichert, L. J. M., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Sever, M.S., Watschinger, B., Jager, K.J., Gansevoort, R.T., Goffin, E., Candellier, A., Vart, P., Noordzij, M., Arnol, M., Covic, A., Lentini, P., Malik, S., Reichert, L. J. M., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Sever, M.S., Watschinger, B., Jager, K.J., and Gansevoort, R.T.
- Abstract
Item does not contain fulltext, BACKGROUND: Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about kidney replacement therapy (KRT) strategy during the pandemic. This study investigated the association of the type of KRT with COVID-19 severity, adjusting for differences in individual characteristics. METHODS: Data on KT recipients and HD patients diagnosed with COVID-19 between 1 February 2020 and 1 December 2020 were retrieved from the European Renal Association COVID-19 Database. Cox regression models adjusted for age, sex, frailty and comorbidities were used to estimate hazard ratios (HRs) for 28-day mortality risk in all patients and in the subsets that were tested because of symptoms. RESULTS: A total of 1670 patients (496 functional KT and 1174 HD) were included; 16.9% of KT and 23.9% of HD patients died within 28 days of presentation. The unadjusted 28-day mortality risk was 33% lower in KT recipients compared with HD patients {HR 0.67 [95% confidence interval (CI) 0.52-0.85]}. In a fully adjusted model, the risk was 78% higher in KT recipients [HR 1.78 (95% CI 1.22-2.61)] compared with HD patients. This association was similar in patients tested because of symptoms [fully adjusted model HR 2.00 (95% CI 1.31-3.06)]. This risk was dramatically increased during the first post-transplant year. Results were similar for other endpoints (e.g. hospitalization, intensive care unit admission and mortality >28 days) and across subgroups. CONCLUSIONS: KT recipients had a greater risk of a more severe course of COVID-19 compared with HD patients, therefore they require specific infection mitigation strategies.
- Published
- 2021
8. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis
- Author
-
Mitra, S., Jayanti, A., Vart, P., Coca, A., Gallieni, M., Øvrehus, M.A., Midtvedt, K., ElHafeez, S. Abd, Gandolfini, I., Büttner, S., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Franssen, C.F., Hemmelder, M.H., Mitra, S., Jayanti, A., Vart, P., Coca, A., Gallieni, M., Øvrehus, M.A., Midtvedt, K., ElHafeez, S. Abd, Gandolfini, I., Büttner, S., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Franssen, C.F., and Hemmelder, M.H.
- Abstract
Item does not contain fulltext, BACKGROUND: Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. METHODS: The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. RESULTS: Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. CONCLUSIONS: This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in th
- Published
- 2021
9. Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome
- Author
-
Jansen, A.M.E., Sriram, J.D., Pluim, D., Maas, R.J.H., Groningen, H. van, Piet, B., Heine, R. ter, Jansen, A.M.E., Sriram, J.D., Pluim, D., Maas, R.J.H., Groningen, H. van, Piet, B., and Heine, R. ter
- Abstract
Contains fulltext : 232540.pdf (Publisher’s version ) (Open Access)
- Published
- 2021
10. Rituximab in Membranous Nephropathy
- Author
-
Gauckler, P., Shin, J.I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., Cheung, C.K., Crnogorac, M., Delbarba, E., Eller, K., Faguer, S., Galesic, K., Griffin, Sian, Hoogen, M.W.F. van den, Hrušková, Z., Jeyabalan, A., Karras, A., King, C., Kohli, H.S., Mayer, G., Maas, R.J.H., Muto, M., Moiseev, S., Odler, B., Pepper, R.J., Quintana, L.F., Radhakrishnan, J., Ramachandran, R., Salama, A.D., Schönermarck, U., Segelmark, M., Smith, L., Tesař, V., Wetzels, J., Willcocks, L., Windpessl, M., Zand, L., Zonozi, R., Kronbichler, A., Gauckler, P., Shin, J.I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., Cheung, C.K., Crnogorac, M., Delbarba, E., Eller, K., Faguer, S., Galesic, K., Griffin, Sian, Hoogen, M.W.F. van den, Hrušková, Z., Jeyabalan, A., Karras, A., King, C., Kohli, H.S., Mayer, G., Maas, R.J.H., Muto, M., Moiseev, S., Odler, B., Pepper, R.J., Quintana, L.F., Radhakrishnan, J., Ramachandran, R., Salama, A.D., Schönermarck, U., Segelmark, M., Smith, L., Tesař, V., Wetzels, J., Willcocks, L., Windpessl, M., Zand, L., Zonozi, R., and Kronbichler, A.
- Abstract
Contains fulltext : 245229.pdf (Publisher’s version ) (Open Access), Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of "the new standard."
- Published
- 2021
11. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
- Author
-
Maas, R.J.H., Gianotten, S., Meijden, W.A.G. van der, Maas, R.J.H., Gianotten, S., and Meijden, W.A.G. van der
- Abstract
Contains fulltext : 245152.pdf (Publisher’s version ) (Closed access)
- Published
- 2021
12. Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome
- Author
-
Jansen, A.M.E., primary, Sriram, J.D., additional, Pluim, D., additional, Maas, R.J.H., additional, van Groningen, H., additional, Piet, B., additional, and ter Heine, R., additional
- Published
- 2021
- Full Text
- View/download PDF
13. Nephron Number as Predictor of Corticosteroid Response in Adult Minimal Change Disease
- Author
-
Berge, B.T. van den, Maas, R.J.H., Berge, B.T. van den, and Maas, R.J.H.
- Abstract
Contains fulltext : 229633.pdf (publisher's version ) (Open Access)
- Published
- 2020
14. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
- Author
-
Gauckler, Philipp, Il Shin, Jae, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, M., Maas, R.J.H., Wetzels, J.F.M., Zonozi, Reza, Kronbichler, Andreas, Gauckler, Philipp, Il Shin, Jae, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, M., Maas, R.J.H., Wetzels, J.F.M., Zonozi, Reza, and Kronbichler, Andreas
- Abstract
Contains fulltext : 226142.pdf (Publisher’s version ) (Open Access)
- Published
- 2020
15. Glomerular disease in 2016: New advances in the treatment of glomerular disease
- Author
-
Maas, R.J.H. and Wetzels, J.F.M.
- Subjects
Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] - Abstract
Item does not contain fulltext
- Published
- 2017
16. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series
- Author
-
Maas, R.J.H., Deegens, J.K.J., Beukhof, J.R., Reichert, L.J., Dam, M.A. ten, Beutler, J.J., Wall-Bake, A.W.L. van den, Rensma, P.L., Konings, C.J.A.M., Geerse, D.A., Feith, G.W., Kuijk, W.H., Wetzels, J.F.M., Maas, R.J.H., Deegens, J.K.J., Beukhof, J.R., Reichert, L.J., Dam, M.A. ten, Beutler, J.J., Wall-Bake, A.W.L. van den, Rensma, P.L., Konings, C.J.A.M., Geerse, D.A., Feith, G.W., Kuijk, W.H., and Wetzels, J.F.M.
- Abstract
Contains fulltext : 174168.pdf (publisher's version ) (Closed access), BACKGROUND: Few studies have examined the treatment and outcome of adult-onset minimal change nephrotic syndrome (MCNS). We retrospectively studied 125 patients who had MCNS with onset in either adulthood or late adolescence. Presenting characteristics, duration of initial treatment and response to treatment, relapse patterns, complications, and long-term outcome were studied. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Patients with new-onset nephrotic syndrome 16 years or older and a histologic diagnosis of MCNS in 1985 to 2011 were identified from pathology records of 10 participating centers. OUTCOMES: Partial and complete remission, treatment resistance, relapse, complications, renal survival. RESULTS: Corticosteroids were given as initial treatment in 105 (84%) patients. After 16 weeks of corticosteroid treatment, 92 (88%) of these patients had reached remission. Median time to remission was 4 (IQR, 2-7) weeks. 7 (6%) patients initially received cyclophosphamide with or without corticosteroids, and all attained remission after a median of 4 (IQR, 3-11) weeks. 13 (10%) patients reached remission without immunosuppressive treatment. One or more relapses were observed in 57 (54%) patients who received initial corticosteroid treatment. Second-line cyclophosphamide resulted in stable remission in 57% of patients with relapsing MCNS. Acute kidney injury was observed in 50 (40%) patients. Recovery of kidney function occurred almost without exception. Arterial or venous thrombosis occurred in 11 (9%) patients. At the last follow-up, 113 (90%) patients were in remission and had preserved kidney function. 3 patients with steroid-resistant MCNS progressed to end-stage renal disease, which was associated with focal segmental glomerulosclerosis lesions on repeat biopsy. LIMITATIONS: Retrospective design, variable treatment protocols. CONCLUSIONS: The large majority of patients who had MCNS with onset in adulthood or late adolescence were treated with corticosteroids
- Published
- 2017
17. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report
- Author
-
Daanen, R.A., Maas, R.J.H., Koornstra, R.H., Steenbergen, E.J., Herpen, C.M.L. van, Willemsen, A.E.C.A.B., Daanen, R.A., Maas, R.J.H., Koornstra, R.H., Steenbergen, E.J., Herpen, C.M.L. van, and Willemsen, A.E.C.A.B.
- Abstract
Item does not contain fulltext, INTRODUCTION: Immune checkpoint inhibitors have taken an important place in the treatment of different types of malignancies. These drugs are known to have specific immune-mediated adverse events. We describe a case of severe nephrotic syndrome secondary to treatment with nivolumab in a patient with renal cell carcinoma. CASE PRESENTATION: A 62-year-old man was treated with nivolumab for papillary renal cell carcinoma type 2 for 8 weeks when he was admitted to the hospital with a severe nephrotic syndrome and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment with high-dose corticosteroids had insufficient effect, but the addition of mycophenolate mofetil resulted in remission of the nephrotic syndrome and recovery of renal function. Proteinuria subsequently relapsed during corticosteroid tapering. CONCLUSIONS: The time course in this patient strongly suggests that the nephrotic syndrome occurred as an adverse drug reaction to nivolumab treatment. If during nivolumab treatment renal insufficiency, hypoalbuminemia, or proteinuria develops, further analysis for a possible nephrotic syndrome is warranted for early detection and treatment of this life-threatening complication.
- Published
- 2017
18. Adult idiopathic nephrotic syndrome: Prognosis, biomarkers and outcome
- Author
-
Maas, R.J.H., Wetzels, J.F.M., Deegens, J.K.J., and Radboud University Nijmegen
- Subjects
Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) - Abstract
Contains fulltext : 150180.pdf (Publisher’s version ) (Open Access) Radboud Universiteit Nijmegen, 21 januari 2016 Promotor : Wetzels, J.F.M. Co-promotor : Deegens, J.K.J.
- Published
- 2016
19. Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy
- Author
-
Maas, R.J.H., Brand, J. van den, Waanders, F., Meijer, E., Goor, H. van, Peters, H.P.E., Hofstra, J.M., Wetzels, J.F.M., Maas, R.J.H., Brand, J. van den, Waanders, F., Meijer, E., Goor, H. van, Peters, H.P.E., Hofstra, J.M., and Wetzels, J.F.M.
- Abstract
Item does not contain fulltext, BACKGROUND: Urinary excretion of alpha-1-microglobulin and beta-2-microglobulin reflects tubular damage and predicts outcome in patients with idiopathic membranous nephropathy with reasonable accuracy. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin are novel biomarkers of tubular damage. We investigated if these markers could improve prediction of outcome in idiopathic membranous nephropathy. METHODS: We measured kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in urine samples from patients with idiopathic membranous nephropathy, who had nephrotic proteinuria and normal renal function. Excretion of alpha-1-microglobulin and beta-2-microglobulin had been measured previously. Progression was defined as a serum creatinine rise >30%, a rise in serum creatinine to an absolute value of >/=135 micromol/L, or a clinical decision to start immunosuppressive therapy. Remission was defined as proteinuria <3.5 g/day and >50% reduction from baseline. RESULTS: Sixty-nine patients were included. Median follow-up was 35 months (interquartile range 18-63 months). Progression occurred in 30 patients (44%), and spontaneous remission in 36 (52%). Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin excretion rates were significantly correlated with each other, and with alpha-1-microglobulin and beta-2-microglobulin. The areas under the receiver operating characteristic curves for progression were 0.75 (0.62-0.87) for kidney injury molecule-1 and 0.74 (0.62-0.87) for neutrophil gelatinase-associated lipocalin. In multivariate analysis with either alpha-1-microglobulin and beta-2-microglobulin, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin did not independently predict outcome. CONCLUSION: Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin excretion rates correlated with excretion rates of other tubular damage markers and predicted outcome in patients with idiopathic
- Published
- 2016
20. Adult idiopathic nephrotic syndrome: Prognosis, biomarkers and outcome
- Author
-
Wetzels, J.F.M., Deegens, J.K.J., Maas, R.J.H., Wetzels, J.F.M., Deegens, J.K.J., and Maas, R.J.H.
- Abstract
Radboud Universiteit Nijmegen, 21 januari 2016, Promotor : Wetzels, J.F.M. Co-promotor : Deegens, J.K.J., Contains fulltext : 150180.pdf (publisher's version ) (Open Access)
- Published
- 2016
21. Minimal change disease and idiopathic FSGS: manifestations of the same disease
- Author
-
Maas, R.J.H., Deegens, J.K.J., Smeets, B., Moeller, M.J., Wetzels, J.F.M., Maas, R.J.H., Deegens, J.K.J., Smeets, B., Moeller, M.J., and Wetzels, J.F.M.
- Abstract
Item does not contain fulltext, Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the key histological findings in patients with idiopathic nephrotic syndrome (INS). Although MCD and idiopathic FSGS are often considered to represent separate entities based on differences in their presenting characteristics, histology and outcomes, little evidence exists for this separation. We propose that MCD and idiopathic FSGS are different manifestations of the same progressive disease. The gradual development of FSGS in patients with non-remitting or relapsing INS has been well documented. Moreover, FSGS is the uniform result of substantial podocyte loss in animal models, and a common feature of virtually all progressive human glomerulopathies. As evidence suggests a common aetiology, the pathogenesis of MCD and idiopathic FSGS should be studied together. In clinical trials, idiopathic FSGS should be considered to represent an advanced stage of disease progression that is less likely to respond to treatment than the earlier stage of disease, which is usually defined as MCD.
- Published
- 2016
22. Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease
- Author
-
Maas, R.J.H., Wetzels, J.F.M., Deegens, J.K.J., Maas, R.J.H., Wetzels, J.F.M., and Deegens, J.K.J.
- Abstract
Item does not contain fulltext
- Published
- 2014
23. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future
- Author
-
Maas, R.J.H., Deegens, J.K.J., Wetzels, J.F.M., Maas, R.J.H., Deegens, J.K.J., and Wetzels, J.F.M.
- Abstract
Item does not contain fulltext, The term idiopathic nephrotic syndrome (iNS) traditionally covers minimal change disease and primary focal segmental glomerulosclerosis (FSGS), now thought to be separate disease entities. Clinical and experimental evidence suggest that circulating permeability factors are involved in their pathogenesis. In the past four decades, many investigators have searched for the responsible factors, thus far with little success. The recent report of the soluble urokinase plasminogen activator receptor as a causative factor in FSGS has received much attention, but again the initially promising findings were not confirmed. We describe the history of the search for permeability factors, discuss the pitfalls that are likely responsible for the lack of success and propose criteria that should be used in future studies when evaluating candidate permeability factors.
- Published
- 2014
24. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis
- Author
-
Meijers, B., Maas, R.J.H., Sprangers, B., Claes, K., Poesen, R., Bammens, B., Naesens, M., Deegens, J.K.J., Dietrich, R., Storr, M., Wetzels, J.F.M., Evenepoel, P., Kuypers, D., Meijers, B., Maas, R.J.H., Sprangers, B., Claes, K., Poesen, R., Bammens, B., Naesens, M., Deegens, J.K.J., Dietrich, R., Storr, M., Wetzels, J.F.M., Evenepoel, P., and Kuypers, D.
- Abstract
Item does not contain fulltext, The soluble urokinase receptor (suPAR) promotes proteinuria and induces focal segmental glomerulosclerosis (FSGS)-like lesions in mice. A serum suPAR concentration cutoff of 3000 pg/ml has been proposed as a clinical biomarker for patients with FSGS. Interestingly, several studies in patients with glomerulopathy found an inverse correlation between the estimated glomerular filtration rate (eGFR) and suPAR. As patients with FSGS present at different eGFRs, we studied the relationship between eGFR and suPAR in a cohort of 476 non-FSGS patients and 54 patients with biopsy-proven idiopathic FSGS. In the non-FSGS patients, eGFR was the strongest significant determinant of suPAR. The proposed cutoff for suPAR in FSGS patients was exceeded in 17%, 39%, and 88% in patients with eGFRs of more than 60, 45-60, and 30-45 ml/min per 1.73 m(2), respectively. In patients with eGFR of <30 ml/min per 1.73 m(2), suPAR exceeded the cutoff in 95% of patients. Levels of suPAR in patients with idiopathic FSGS overlapped with non-FSGS controls and for any given eGFR did not discriminate FSGS cases from non-FSGS controls. In the overall cohort, there was a negative association between idiopathic FSGS and suPAR, and idiopathic FSGS was not an independent predictor of FSGS concentration over 3000 pg/ml. Thus, this study does not support an absolute, eGFR-independent, suPAR concentration cutoff as a biomarker for underlying FSGS pathology and questions the validity of relative, eGFR-dependent suPAR cutoff values.
- Published
- 2014
25. Serum suPAR in patients with FSGS: trash or treasure?
- Author
-
Maas, R.J.H., Deegens, J.K.J., Wetzels, J.F.M., Maas, R.J.H., Deegens, J.K.J., and Wetzels, J.F.M.
- Abstract
Item does not contain fulltext, The urokinase-type plasminogen activator receptor (uPAR) has important functions in cell migration. uPAR can be shed from the cell membrane resulting in soluble uPAR (suPAR). Further cleavage gives rise to shorter fragments with largely unknown functions. Recent studies have demonstrated that both overexpression of uPAR on podocytes and the administration of suPAR cause proteinuria in mice. The common pathogenic mechanism involves the activation of podocyte beta3-integrin. Increased activation of beta3-integrin is also observed in patients with focal and segmental glomerulosclerosis (FSGS). These observations form the basis for the hypothesis that suPAR may be the circulating factor causing FSGS. A recent study fosters this idea by demonstrating increased suPAR levels in the serum of patients with FSGS and reporting an association with recurrence after transplantation and response to plasmapheresis. However, this study was heavily biased, and subsequent studies have given conflicting results. Although the experimental work is very suggestive, at present there is no proof that any known human suPAR fragment causes FSGS in humans. We therefore suggest that the measurement of suPAR using currently available assays has absolutely no value at the present time in decision-making in routine clinical practice.
- Published
- 2013
26. A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation
- Author
-
Maas, R.J.H., Deegens, J.K.J., Brand, J. van den, Cornelissen, E.A.M., Wetzels, J.F.M., Maas, R.J.H., Deegens, J.K.J., Brand, J. van den, Cornelissen, E.A.M., and Wetzels, J.F.M.
- Abstract
Contains fulltext : 118458.pdf (publisher's version ) (Open Access), BACKGROUND: Focal segmental glomerulosclerosis (FSGS) is a frequent cause of end-stage renal disease. Renal transplantation in patients with FSGS is often complicated by disease recurrence, which is associated with poor outcome. There are no tests that reliably predict recurrence of FSGS after transplantation. The aim of this study was to evaluate if clinical criteria can identify patients at high risk for recurrent disease. METHODS: We retrospectively studied 94 patients who received a first renal transplant at a median age of 37 years (range 5-69 years). Patients were assigned to one of three groups: familial or genetic FSGS (group I; n=18), secondary FSGS (group II; n=10) and idiopathic FSGS (group III; n=66). Pretransplant clinical characteristics were analyzed to determine predictors of a recurrence after transplantation. RESULTS: FSGS only recurred in patients with idiopathic FSGS (group III; 42%). Patients with a recurrence had a significantly lower serum albumin, higher 24-hour proteinuria and higher estimated glomerular filtration rate at diagnosis. Serum albumin at diagnosis was the only independent predictor of a recurrence in patients with idiopathic FSGS. Patients with recurrent FSGS had more acute rejection episodes (54% vs. 27%, P =0.02) and lower five year graft survival compared to patients without a recurrence (50 vs. 82%, P <0.01). CONCLUSIONS: Clinical criteria allow identification of patients at high risk of recurrent FSGS after renal transplantation. This information can be used in the counseling and management of patients with FSGS.
- Published
- 2013
27. Serum-soluble urokinase receptor concentration in primary FSGS
- Author
-
Maas, R.J.H., Wetzels, J.F.M., and Deegens, J.K.J.
- Subjects
Renal disorder [IGMD 9] - Abstract
Item does not contain fulltext 01 mei 2012
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.